The Latest Breaking News from Eli Lilly

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?

While understanding so-called ‘options math’ can provide interesting context and color, the real alpha generation comes from an entirely different framework.

Eli Lilly and Co (NYSE:LLY) released underwhelming data from a Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.

Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone.

September S&P 500 E-Mini futures (ESU25) are trending up +0.32% this morning, capping a week dominated by tariff and geopolitical developments, as well as a wave of earnings, with investors weighing U.S. President Donald Trump’s efforts to tighten his grip on the Federal Reserve.

The U.S. stock market saw a mixed performance today, with the Nasdaq gaining over 70 points, reflecting a 0.35% increase to 21,242.70. Meanwhile, the SP 500 fell by 0.08% to 6,340, and the Dow Jones Industrial Average experienced a decline of 0.5% to settle at 43,968.64.

The S&P 500 Index ($SPX ) (SPY ) Thursday closed down -0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.51%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.32%. September E-mini S&P futures (ESU25 ) fell -0.04%, and September E-mini Nasdaq futures (NQU25...

The main indexes finished well off their session highs after a disappointing batch of corporate earnings reports.

Results of study suggest orforglipron could be a simpler, cheaper alternative to injections